KAUST researchers have discovered that combining ultraviolet sunlight with phages increases the susceptibility of antibiotic-resistant bacteria to sunlight disinfection. This breakthrough addresses the growing threat of antimicrobial resistance, as the rate of discovering new antibiotics has slowed. The team demonstrated this method's effectiveness against a pathogenic E. coli strain found in Saudi wastewater. Why it matters: This research offers a promising alternative to traditional antibiotics, particularly relevant in regions like Singapore and the GCC where treated wastewater is a crucial water supply source.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.
KAUST researchers led by Professor Pei-Ying Hong reported new insights into bacterial transformation, potentially impacting wastewater treatment policies. Professor Havard Rue's group released a new statistical package for modeling non-Gaussian datasets, compatible with commercial software. These achievements highlight KAUST's contributions to environmental science and statistical computing. Why it matters: These research outputs strengthen KAUST's reputation as a leading research institution in Saudi Arabia, with practical implications for environmental policy and advanced data analysis.
A KAUST scientist led a global call for climate solutions, published simultaneously by 14 academic journals and released at COP29. The publication, prepared by 18 scientists, urges international governments to deploy microbial 'vaccines' against climate change. Six simple 'vaccine' examples are outlined, including carbon sequestration boosters and methane busters. Why it matters: This coordinated effort highlights the urgency of addressing climate change and KAUST's leading role in microbial solutions.
KAUST researchers collaborated on a study published in Nature analyzing microbiomes in 170 glacier-fed streams worldwide. The study, led by EPFL, identified a unique microbiome distinct from other cryospheric systems, with almost half the bacteria endemic to specific mountain ranges. KAUST's sequencing efforts helped create a global atlas of these threatened microbiomes. Why it matters: Understanding these microbiomes is crucial for monitoring the impact of climate change on vital freshwater sources originating from glaciers.
KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.